Trial Of Oral Thalidomide, Celecoxib, Etoposide And Cyclophosphamide In Adult Patients With Relapsed Or Progressive Malignant Gliomas
- Determine the efficacy of thalidomide, celecoxib, etoposide, and cyclophosphamide, in
terms of 6-month progression-free survival, in patients with relapsed or refractory
- Determine the overall survival of patients treated with this regimen.
- Determine the toxic effects of this regimen in these patients.
- Determine the radiographic response in patients treated with this regimen.
OUTLINE: This is a multicenter study.
Patients receive oral thalidomide once daily and oral celecoxib twice daily on days 1-42,
oral etoposide once daily on days 1-21, and oral cyclophosphamide once daily on days 22-42.
Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
Patients are followed every 2 months.
PROJECTED ACCRUAL: A total of 48 patients (32 with glioblastoma multiforme and 16 with
anaplastic glioma) will be accrued for this study within 2 years.
Masking: Open Label, Primary Purpose: Treatment
Patrick Y. Wen, MD
Dana-Farber Cancer Institute
United States: Federal Government
|Massachusetts General Hospital Cancer Center||Boston, Massachusetts 02114|
|Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute||Boston, Massachusetts 02115|
|Brigham and Women's Hospital||Boston, Massachusetts 02115|